TWiV 988: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses FDA authorizing the first over-the-counter at-home test to detect both influenza and COVID-19, monoclonal antibody for the prevention of respiratory syncytial virus infection in infants and children, epidemiologic characteristics of SARS-CoV-2 recombinant variant XBB.1.5, COVID-19 vaccines vs pediatric hospitalization, maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life, immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children, fatal fulminant cerebral edema in six children with SARS-CoV-2 Omicron BA.2 infection in Taiwan, certifying deaths due to COVID-19, efficacy of first dose of COVID-19 vaccine vs no vaccination on symptoms of patients with long COVID, and the effect of COVID-19 vaccination on long COVID.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• FDA authorizes over-the-counter at-home test to detect both Influenza and COVID-19 (FDA)
• Monoclonal antibody for the prevention of RSV in infants and children (JAMA)
• Epidemiologic characteristics of SARS-CoV-2 variant XBB.1.5 (CDC)
• COVID-19 vaccines vs pediatric hospitalization (Cell)
• Maternal SARS-CoV-2 vaccination and infant protection during the first six months of life (Nature)
• Immunoglobulin, glucocorticoid, or combination therapy for MIS in children (The Lancet)
• Fatal Fulminant Cerebral Edema in children with SARS-CoV-2 Omicron BA.2 infection (JPID)
• Certifying deaths due to COVID-19 (CDC)
• Efficacy of first dose of COVID-19 vaccine vs no vaccination on patients with Long COVID (BMJ)
• Effect of COVID-19 vaccination on long COVID (BMJ)
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin's treatment guide (pdf)
• Letters read on TWiV 988
• Don't crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]